Investigational Antipsychotic Demonstrates Efficacy Without Blocking Dopamine Receptor
Investigational agent KarXT is a first-in-class muscarinic receptor agonist demonstrating antipsychotic efficacy and safety in short- and long-term clinical trials.
Source: psychiatrictimes.com